Literature DB >> 21122509

Methotrexate-induced pneumonitis in a patient with Crohn's disease.

Giovanna Margagnoni1, Valeria Papi, Annalisa Aratari, Luca Triolo, Claudio Papi.   

Abstract

Pulmonary toxicity is a well recognised but infrequent adverse event of treatment with methotrexate. The vast majority of cases have occurred in patients with rheumatoid arthritis; here we present the case of a 44-year old woman with ileo-colonic Crohn's disease who developed methotrexate pneumonitis. The patient had a 10 year history of Crohn's disease and, in the last 18 months, she was treated with oral methotrexate because of steroid-dependency and intolerance to thiopurines. She was admitted to the hospital because of acute dyspnoea, non-productive cough and fever. High-resolution CT scan showed diffuse bilateral areas of ground-glass opacity, and pulmonary function tests disclosed a mild obstructive pattern with a decrease in carbon monoxide diffusing capacity. Blood cultures for pathogenic bacteria or fungi were negative as well as serologic tests against major pneumotropic agents. Methotrexate-induced lung injury was considered: the drug was discontinued and the patient received a steroid course with rapid symptomatic improvement. After 4 weeks pulmonary function tests and high-resolution chest CT scan were normal. To our knowledge this is the second reported case of methotrexate-induced pneumonitis occurring in a patient with Crohn's disease. A definite diagnosis has been made not invasively according to clinical, laboratory and radiological criteria and excluding any infectious aetiology of the pulmonary findings.
Copyright © 2009 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122509     DOI: 10.1016/j.crohns.2009.11.007

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  7 in total

Review 1.  Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.

Authors:  Leon P McLean; Raymond K Cross
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2014-02-04       Impact factor: 3.869

Review 2.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 3.  Pulmonary manifestations of Crohn's disease.

Authors:  De-Gan Lu; Xiao-Qing Ji; Xun Liu; Hong-Jia Li; Cai-Qing Zhang
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 4.  Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases.

Authors:  Hans H Herfarth; Michael D Kappelman; Millie D Long; Kim L Isaacs
Journal:  Inflamm Bowel Dis       Date:  2016-01       Impact factor: 5.325

Review 5.  Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials.

Authors:  Richard Conway; Candice Low; Robert J Coughlan; Martin J O'Donnell; John J Carey
Journal:  BMJ       Date:  2015-03-13

6.  Respiratory involvement in inflammatory bowel diseases.

Authors:  Nadia D'Andrea; Rossana Vigliarolo; Claudio M Sanguinetti
Journal:  Multidiscip Respir Med       Date:  2010-06-30

Review 7.  Methotrexate pneumonitis in a patient with Crohn's disease, during the COVID pandemic: An unusual clinical case and review of the literature.

Authors:  Andrea de Los Mozos Ruano; Diego Casas Deza; Roberto Calvo Galindo; María Patricia Solana Hidalgo; Nerea Aguirre Portu; Ángel Aranda Alonso; Erardo Ernesto Meriño Ibarra; Santiago García López
Journal:  Gastroenterol Hepatol       Date:  2020-09-16       Impact factor: 5.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.